Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that CEO Greg Divis will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 25 at 8:30 a.m. E.T. This event aims to share insights into the company's innovative biopharmaceutical solutions. A live webcast and an archived recording will be available on the company's Investor Relations website for 90 days following the conference. Avadel focuses on developing medications for challenges faced by patients, notably their lead candidate, FT218, designed for narcolepsy treatment.

News Market Reaction – AVDL

-4.85%

-4.85% Session move

In the trading session that priced this news, AVDL declined 4.85%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

When is the H.C. Wainwright Global Investment Conference for Avadel Pharmaceuticals?

The H.C. Wainwright Global Investment Conference will take place on May 25, 2022, at 8:30 a.m. E.T.

Who is representing Avadel Pharmaceuticals at the investment conference?

Greg Divis, the Chief Executive Officer of Avadel Pharmaceuticals, will participate in the conference.

Where can I find the webcast of Avadel's conference participation?

The live webcast and archived recording will be available on Avadel’s Investor Relations website for 90 days after the event.

What is Avadel Pharmaceuticals' lead drug candidate?

Avadel's lead drug candidate is FT218, an investigational formulation for treating excessive daytime sleepiness and cataplexy in narcolepsy patients.

What is the stock symbol for Avadel Pharmaceuticals?

The stock symbol for Avadel Pharmaceuticals is AVDL.